All In Biotech

Drug Trial Radar · NCT04238364

A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy Volunteers

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study Followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics of EI1071 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

58

Actual

Start

Dec 27, 2019

Primary completion

Dec 16, 2021

Study completion Jan 10, 2022

Sponsor

Sponsor type
Industry
Collaborators
Parexel
First posted
Jan 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This was a first-in-human study to determine the safety, tolerability, and pharmacokinetics of EI1071 after single and multiple doses in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

  • EI-1071Drug

    EI-1071 Tablet(s)

  • PlaceboDrug

    Matching Placebo Tablet(s)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. After single ascending doses, number of subjects with treatment-emergent adverse events (TEAEs) after dosing with EI-1071Time frame: Up to 7 days
  2. After multiple ascending doses, number of subjects with TEAEs after dosing with EI-1071Time frame: Up to 21 days
  3. After multiple ascending doses, number of subjects with adverse events (AEs) leading to discontinuation in the EI-1071 cohorts.Time frame: Up to 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel Early Phase Clinical Unit

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.